Leap Therapeutics, Inc.
LPTX
$0.377
-$0.0134-3.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.75% | -3.89% | -11.71% | -5.37% | -6.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.80% | 8.64% | 28.54% | 46.19% | -65.66% |
| Operating Income | -8.80% | -8.64% | -28.54% | -46.19% | 65.66% |
| Income Before Tax | -11.69% | -24.78% | -27.54% | -52.07% | 66.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.69% | -23.79% | -32.71% | -52.07% | 66.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.69% | -23.79% | -32.71% | -52.07% | 66.99% |
| EBIT | -8.80% | -8.64% | -28.54% | -46.19% | 65.66% |
| EBITDA | -8.83% | -8.67% | -28.57% | -46.23% | 65.67% |
| EPS Basic | 26.90% | 17.80% | 13.08% | 42.81% | 84.19% |
| Normalized Basic EPS | 26.87% | -63.21% | 16.49% | 43.47% | 84.20% |
| EPS Diluted | 26.90% | 17.80% | 13.08% | 42.81% | 84.19% |
| Normalized Diluted EPS | 26.87% | -63.21% | 16.49% | 43.47% | 84.20% |
| Average Basic Shares Outstanding | 52.77% | 52.86% | 52.70% | 165.95% | 108.85% |
| Average Diluted Shares Outstanding | 52.77% | 52.86% | 52.70% | 165.95% | 108.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |